The clinical significance of smoldering multiple myeloma (MM) is, as of recently, becoming much more important, especially in those patients who progress to MM quite rapidly. Speaking from the 1st European Myeloma Network (EMN) Meeting 2018, in Turin, Italy, Robert Kyle, MD, of the Mayo Clinic, Rochester, MN, explains just how important it is to monitor patients in the smoldering MM stage. Prof. Kyle emphasizes how, with careful monitoring, diagnostic rates of smoldering MM may even decrease if it progresses at the same rate of monoclonal gammopathy of undetermined significance (MGUS), allowing to be caught early enough to monitor and treat.
